Reducing Toxicity Associated with Teclistamab: The Role of Prophylactic Tocilizumab and Timing for Immunoglobulin Replacement in a National Cohort Study

1

Teclistamab is a bispecific antibody effective against relapsed or refractory multiple myeloma but has a challenging safety profile.
2

Cytokine-release syndrome (CRS) occurs in most patients during step-up dosing, with 72% affected in the MajesTEC-1 study.
3

Prophylactic tocilizumab administration before the first step-up dose significantly reduces CRS incidence to approximately 10%.
4

Infections occurred in 79% of patients in the MajesTEC-1 study, with real-world cohorts confirming high infection rates.
5

The ABCD study evaluated safety management of Teclistamab treatment in Denmark, focusing on CRS prevention and infection prophylaxis.

American Journal Of Hematology

by Astrid Hundebøll Torpe, Jonathan Thorsen, Gustav Mathiasen, Katrine Fladeland Iversen, Sarah Farmer, Thomas Lund, Charlotte Toftmann Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Ølholm Vase, Elena Manuela Teodorescu, Morten Salomo, Christina Wennerström, Tobias S. Slørdahl, Agoston Gyula Szabo
May 26, 2026

1